BD Veritor System Rapid SARS-CoV-2 Test Instructions For Use
- June 2, 2024
- BD
Table of Contents
- Veritor™ System For Rapid Detection of SARS-CoV-2
- For Rapid Detection of SARS-CoV-2
- INTENDED USE
- SUMMARY AND EXPLANATION OF THE TEST
- PRINCIPLES OF THE PROCEDURE
- REAGENTS
- Materials Provided:
- Materials Required but not provided:
- Optional Equipment:
- WARNINGS AND PRECAUTIONS
- STORAGE
- SPECIMEN COLLECTION AND HANDLING
- DOs and DON’Ts of Sample Collection
- TEST PROCEDURE
- Process the Specimen or Control Swab
- After processing the swab in the extraction reagent, the sample should
- A. Using a BD Veritor Plus Analyzer in “Analyze Now” mode:
- INTERPRETATION OF RESULTS
- REPORTING OF RESULTS
- QUALITY CONTROL
- EXTERNAL POSITIVE AND NEGATIVE CONTROLS
- LIMITATIONS OF THE PROCEDURE
- CONDITIONS OF AUTHORIZATION FOR THE LABORATORY (APPLICABLE IN THE USA)
- Customer Support
- CLINICAL PERFORMANCE
- ANALYTICAL PERFORMANCE
- CROSS REACTIVITY (ANALYTICAL SPECIFICITY)
- HIGH DOSE HOOK EFFECT
- TECHNICAL SUPPORT
- REFERENCES
- Read User Manual Online (PDF format)
- Download This Manual (PDF format)
Veritor™ System For Rapid Detection of SARS-CoV-2
Kit configured for testing nasal swab samples freshly collected, processed and dispensed directly onto assay test device. In the USA: For use under an Emergency Use Authorization only.
For Rapid Detection of SARS-CoV-2
For In Vitro Diagnostic Use
For use with the BD Veritor™ Plus Analyzer running firmware version 5.4 or
later
In the USA: For use under an Emergency Use Authorization only
Please read these instructions completely before beginning testing of
specimens.
INTENDED USE
The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is a chromatographic
digital immunoassay intended for the direct and qualitative detection of SARS-
CoV-2 nucleocapsid antigens in nasal swabs fromindividuals who are suspected
of COVID-19 by their healthcare provider within the first five days of the
onset of symptoms. In the USA, testing is limited to laboratories certified
under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.
§263a, that meet
he requirements to perform moderate, high, or waived complexity tests. This
test is authorized for use at the Point of Care (POC), i.e., in patient care
settings operating under a CLIA Certificate of Waiver, Certificate of
Compliance, or Certificate of Accreditation. Results are for the
identification of SARS-CoV-2 nucleocapsid antigen. This antigen is generally
detectable in upper respiratory samples during the acute phase of infection.
Positive results indicate the presence of viral antigens, but clinical
correlation with patient history and other diagnostic information is necessary
to determine infection status. Positive results do not rule out bacterial
infection or co-infection with other viruses. The agent detected may not be
the definite cause of disease. Laboratories within the United States and its
territories are required to report all positive results to the appropriate
public health authorities.
Negative results should be treated as presumptive, do not rule out SARS CoV-2
infection and should not be used as the sole basis for treatment or patient
management decisions, including infection control decisions. Negative results
should be considered in the context of a patient’s recent exposures, history
and the presence of clinical signs and symptoms consistent with COVID-19, and
confirmed with a molecular assay, if necessary, for patient management. The BD
Veritor System for Rapid Detection of SARS-CoV-2 is intended for use by
trained clinical laboratory personnel specifically instructed and trained in
the techniques of in vitro diagnostic procedures, and proper infection control
procedures and individuals similarly trained in point of care settings. In the
United States, the BD Veritor System for Rapid Detection of SARS-CoV-2 is only
for use under the Food and Drug Administration’s Emergency Use Authorization.
SUMMARY AND EXPLANATION OF THE TEST
confirmed human infections worldwide. Cases of severe illness and deaths have
been reported. On February 11, 2020 the International Committee for Taxonomy
of Viruses (ICTV) renamed the virus SARS-CoV-2.2
The median incubation time is estimated to be approximately 5 days 3 with
symptoms estimated to be present within 12 days of infection. The symptoms of
COVID-19 are similar to other viral respiratory diseases and include fever,
cough, shortness of breath.
The BD Veritor System for Rapid Detection of SARS-CoV-2 is a rapid
(approximately 15 minutes) chromatographic digital immunoassay for the direct
detection of the presence or absence SARS-CoV-2 antigens in respiratory
specimens taken from patients with signs and symptoms who are suspected of
COVD-19. The test is intended for interpretation in both laboratory and near
patient testing environments only with the BD Veritor Plus Analyzer
Instrument. The test is not intended to be interpreted visually. Procedures to
evaluate test devices depend on the BD Veritor Plus Analyzer workflow
configuration chosen. In Analyze Now mode , the instrument evaluates assay
devices after manual timing of their development. In Walk Away mode,
devices are inserted immediately after application of the specimen, and timing
of assay development and analysis is automated. Additionally, connection of a
BD Veritor Plus Analyzer to a printer or IT system is possible if desired.
Additional result documentation capabilities are possible with the integration
of a BD Veritor InfoScan (“InfoScan”) module. Please refer to the BD Veritor
Plus Analyzer Instructions for Use for details on how to implement these
features.
PRINCIPLES OF THE PROCEDURE
The BD Veritor System consists of a dedicated opto-electronic interpretation instrument and immunochromatographic assays for the qualitative detection of antigens from pathogenic organisms in samples processed from respiratory specimens. The BD Veritor System for Rapid Detection of SARS-CoV-2 is designed to detect the presence or absence of SARS-CoV-2 nucleocapsid proteins in respiratory samples from patients with signs and symptoms of infection who are suspected of COVID-19. When specimens are processed and added to the test device, SARS-CoV-2 antigens present in the specimen bind to antibodies conjugated to detector particles in the test strip. The antigen-conjugate complexes migrate across the test strip to the reaction area and are captured by a line of antibodies bound on the membrane. A positive result is determined by the BD Veritor Plus Analyzer when antigen-conjugate is deposited at the Test “T” position and the Control “C” position on the assay device. The instrument analyzes and corrects for non-specific binding and detects positives not recognized by the unaided eye to provide an objective result.
REAGENTS
The following components are included in the BD Veritor System for Rapid Detection of SARS-CoV-2 kit.
Materials Provided:
Materials Required but not provided:
- BD Veritor™ Plus Analyzer (Cat. No. 256066)
- timer
- tube rack for specimens
- any necessary personal protective equipment
Optional Equipment:
- BD Veritor InfoScan Module (Cat. No. 256068)
- USB Printer cable for BD Veritor Plus Analyzer (Cat. No. 443907)
- Epson Printer model TM-T20 II
- BD Veritor Plus Connect (contact BD Technical Services for details).
WARNINGS AND PRECAUTIONS
-
For in vitro diagnostic use. In the USA, only for use under an Emergency Use Authorization.
-
In the USA, this test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests and at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
-
This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, in the USA, this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes
COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b (1), unless the authorization is terminated or revoked sooner. -
Do not use this kit beyond the expiration date printed on the outside carton.
-
Do not use the kit to evaluate patient specimens if either the positive control swab or negative control swab fail to give expected results.
-
Test results are not meant to be visually determined. All test results must be determined using the BD Veritor Plus Analyzer.
-
To avoid erroneous results, specimens must be processed as indicated in the assay procedure section.
-
Do not reuse any BD Veritor System test device or kit components.
-
When collecting a nasal swab sample, use the nasal swab supplied in the kit.
-
Proper specimen collection, storage and transport are critical to the performance of this test.
-
Specific training or guidance is recommended if operators are not experienced with specimen collection and handling procedures. Wear protective clothing such as laboratory coats, disposable gloves, and eye protection when specimens are collected and evaluated.
-
Pathogenic microorganisms, including hepatitis viruses and Human Immunodeficiency Virus, may be present in clinical specimens. Standard precautions and institutional guidelines should always be followed in handling, storing, and disposing of all specimens and all items contaminated with blood or other body fluids.
-
The SARS-CoV-2 positive control swabs have been prepared from recombinant viral proteins and do not contain infectious material.
-
Dispose of used BD Veritor System test devices as biohazardous waste in accordance with federal, state andlocal requirements.
-
Reagents contain sodium azide, which is harmful if inhaled, swallowed or exposed to skin. Contact with acids produces very toxic gas. If there is contact with skin, wash immediately with plenty of water. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up.
-
Test devices used in a laminar flow hood or in areas with high air flow should be covered during test development to ensure proper sample flow.
-
For additional information on hazard symbols, safety, handling and disposal of the components within this kit, pleaserefer to the Safety Data Sheet (SDS) located at bd.com.
STORAGE
Kits may be stored at 2–30 °C. DO NOT FREEZE. Reagents and devices must be at room temperature (15–30 °C) when used for testing.
SPECIMEN COLLECTION AND HANDLING
Specimen Collection and Preparation
Acceptable specimens for testing with this kit include nasal swab specimens obtained by the dual nares collection method. It is essential that correct specimen collection and preparation methods be followed. Specimens obtained early during symptom onset will contain the highest viral titers; specimens obtained after five days of symptoms are more likely to produce negative results when compared to an RT-PCR assay. Inadequate specimen collection, improper specimen handling and/or transport may yield a falsely negative result; therefore, training in specimen collection is highly recommended due to the importance of specimen quality for generating accurate test results.
Specimen Transport and Storage
Freshly collected specimens should be processed as soon as possible, but no later than one hour after specimen collection. It is essential that correct specimen collection and preparation methods be followed.
Nasal Swab Specimen Collection
-
The BD Veritor System Kit includes swabs for nasal specimen collection.
-
Insert the swab into one nostril of the patient. The swab tip should be inserted up to 2.5 cm (1 inch) from the edge of the nostril. Roll the swab 5 times along the mucosainside the nostril to ensure that both mucus and cells are collected.
-
Using the same swab, repeat this process for the other nostril to ensure that an adequate sample is collected from both nasal cavities.
-
Withdraw the swab from the nasal cavity. The sample is now ready for processing using the BD Veritor System SARS-CoV-2 kit.
DOs and DON’Ts of Sample Collection
- Do collect sample as soon as possible after onset of symptoms.
- Do test sample immediately.
- Use only swabs provided with the kit.
- Refer to: Interim Guidelines for Collecting, Handling and Testing Clinical Specimens from persons for COVID-19 at https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical specimens.html
TEST PROCEDURE
Reagents, specimens and devices must be at room temperature (15–30 °C) for
testing.
This BD Veritor System assay kit is only intended for nasal swab specimens
that are collected and tested directly (i.e., swabs that have NOT been placed
in transport media). The kit includes a pre-diluted processing reagent in a
ready to use “unitized” tube. This kit IS NOT INTENDED for testing liquid
samples such as wash or aspirate samples or swabs in transport media as
results can be compromised by over dilution.
Getting ready to test
The following steps assume that the BD Veritor Plus Analyzer is ready to use.
To choose or change any BD Veritor Plus Analyzer settings, see the BD Veritor
Plus Analyzer Instructions for Use, section 4.7. A printer is not necessary to
display results. However, if your facility has chosen to connect the BD
Veritor Plus Analyzer to a printer, check that the BD Veritor Plus Analyzer is
plugged into a power source, paper supply is adequate and any necessary
network connections are enabled before testing.
Freshly collected specimens should be processed within 1 hour.
Procedure for Nasal Swabs or control swabs:
Step 1:
- Remove one extraction reagent tube/tip and one BD Veritor System test device from its foil pouch immediately before testing.
- Label one test device and one extraction reagent tube for each specimen or control to be tested.
- Place the labeled extraction reagent tube(s) in a rack in the designated area of the workspace.
Process the Specimen or Control Swab
Step 2:
• Remove and discard the cap from the extraction reagent tube.
Step 3:
• Insert the swab into the tube and plunge the swab up and down in the fluid
for aminimum of 15 seconds, taking care not to splash contents out of the
tube.
Step 4:
• Remove the swab while squeezing the sides of the tube to extract the liquid
from the swab
Step 5:
• Press the attached tip firmly onto the extraction reagent tube containing
the
processed sample (threading or twisting is not required). Mix thoroughly by
swirling or flicking the bottom of the tube.
NOTE: Do not use tubes or tips from any other product, including other
products from BD or other manufacturers.
After processing the swab in the extraction reagent, the sample should
be analyzed within 30 minutes.
A. Using a BD Veritor Plus Analyzer in “Analyze Now” mode:
Step 6A: Adding the specimen to the test device
• Invert the extraction reagent tube and hold it vertically (approximately one
inch above the sample well).
• Gently squeeze the ridged body of the tube, dispensing three (3) drops of
the processed specimen into the sample well.
• Excess volume remains for retesting if necessary.
NOTE : Squeezing the tube too close to the tip may cause leakage.
Step 7A: Timing test development
• After adding the sample, allow the test to run for 15 minutes before
inserting the test device into the BD Veritor Plus Analyzer.
• During incubation time, turn the BD Veritor Plus Analyzer on by pressing the
blue power button once.
_ NOTE: If running test under laminar flow hood, cover test device to
avoid _inconsistent flow.
Step 8A : Using the BD Veritor Plus Analyzer
• The BD Veritor Plus Analyzer will complete a self-test before it is ready
for use. After the self-test the display window shows “INSERT TEST DEVICE OR
DOUBLE-CLICK BUTTON FOR WALK AWAY MODE”.
• INSERT THE TEST DEVICE when the 15-minute assay development time is
complete.
• The status of the assay analysis process appears in the display window.
Follow the on-screen prompts to complete the procedure. Do not touch the
Instrument or remove the test device until the result appears.
• When analysis is complete, the test result appears in the display window.
Step 9A : Record the Result before removing the test device
Step 6B : Starting Walk Away Mode
• Turn the BD Veritor Plus Analyzer on by pressing the blue power button once.
• When the display window reads: “INSERT TEST DEVICE OR DOUBLE-CLICK FOR WALK
AWAY MODE”, Double-click the blue power button.
• The display window reads “ADD SPECIMEN TO TEST DEVICE AND INSERT
IMMEDIATELY”.
Step 7B: Adding the specimen to the test device
• Invert the tube, holding it vertically (approximately one inch above the BD
Veritor System test device sample well).
• Gently squeeze the ridged body of the tube, dispensing three (3) drops of
the processed specimen into the sample well.
• Excess volume remains for retesting if necessary.
NOTE: Squeezing the tube too close to the tip may cause leakage.
_ CAUTION: A countdown timer displays the time remaining for test
insertion. _Walk Away mode must be activated again when this timer expires.
Confirm timer is visible and Walk Away mode is activated before inserting
test device.
Step 8B: Starting the development and reading sequence
• Insert the test device into the slot on the right side of the BD Veritor
Plus Analyzer. The test device must remain horizontal to prevent spilling the
specimen out of the sample well
• “DO NOT DISTURB TEST IN PROGRESS” appears in the display window. Automatic
timing of the assay development, image processing and result analysis begins.
• The display window shows the remaining analysis time.
Do not touch the BD Veritor Plus Analyzer or remove the test device during
this
process. Doing so will abort the assay analysis.
Step 9B: Record the Result
• When analysis is complete, the test result appears in the display window.
Record the result and discard the test
device appropriately.
Step 6C: Adding the specimen to the test device
• Invert the extraction reagent tube and hold it vertically (approximately one
inch above the sample well).
• Gently squeeze the ridged body of the tube, dispensing three (3) drops of
the processed specimen into the sample well.
• Excess volume remains for retesting if necessary.
NOTE: Squeezing the tube too close to the tip may cause leakage.
Step 7C: Timing development
• Allow the test to develop for 15 minutes.
_ CAUTION : incorrect results may occur if development time is less than
15 minutes. Some _lines may appear on the device sooner. Do not read device
visually.
• If running the test in a laminar flow hood or in an area with heavy
ventilation, cover test device to avoid inconsistent flow.
Step 8C: Using the BD Veritor Plus Analyzer
During the incubation time, turn on the BD Veritor Plus Analyzer by pressing
the blue button once. The display window briefly shows “SCAN CONFIG BARCODE.”
This is an opportunity to change the configuration of the BD Veritor Plus
Analyzer. Ignore this message and postpone this process when an assay is
awaiting analysis. Please refer to the BD Veritor Plus Analyzer Instructions
for Use for configuration steps.
• When assay development time is complete and the BD Veritor Plus Analyzer
display window reads “INSERT TEST DEVICE OR DOUBLE-CLICK FOR WALK AWAY MODE”,
insert the BD Veritor System SARS-CoV-2 device into the slot on the right side
of the BD Veritor Plus Analyzer.
Step 9C: Using the barcode scanner
• Follow the prompts on the display screen to complete any required barcode
scans of:
– OPERATOR ID
– SPECIMEN ID and/or
– KIT LOT NUMBER
- Prompts for each scanning step appear in the display window for only 30 seconds. Failure to complete scans during that time will cause the BD Veritor Plus Analyzer to default to the beginning of step 8C. To restart this step, remove and reinsert the test device to initiate a new reading sequence.
- Move barcodes slowly toward the window until a confirmation tone sounds. The scanned barcode value appears in the next display window.
- The BD Veritor Plus Analyzer can record the Kit Lot Number and expiration date in the test record but does not restrict the use of expired or inappropriate reagents. Management of expired materials is the responsibility of the user.
After required scans are completed, the BD Veritor Plus Analyzer displays a
countdown timer and test analysis begins.
• Do not touch the BD Veritor Plus Analyzer or remove the test device during
this process. Doing so will abort the assay analysis.
• When analysis is complete a result appears in the display window. If
configured to display, the specimen ID barcode value also appears. If a
printer is connected, specimen ID and result are automatically printed. If a
printer is not connected, record the result before removing the assay device.
ATTENTION: TEST Results are NOT maintained in the display window when the device is removed or if the BD Veritor Plus Analyzer is left unattended for more than 15 minutes (60 minutes if AC power adapter is connected).
Step 10C: Remove the test device
• Remove and then discard the test device appropriately. The display will show
“INSERT TEST DEVICE OR DOUBLE-CLICK BUTTON FOR WALK AWAY MODE” to indicate the
BD Veritor Plus Analyzer is ready to perform another test.If the BD Veritor
Plus Analyzer is connected to an LIS, a steady ENVELOPE symbol will appear to
indicate that results are awaiting transmission. If a network connection is
not detected while the ENVELOPE symbol is still displayed, the BD Veritor Plus
Analyzer will queue all untransmitted results and attempt to transmit them
when reconnected. If it is powered off during this time, it will attempt to
transmit as soon as power is restored, and connection is re-established. A
flashing envelope indicates that data are in the process of being transmitted.
Step 6D: Starting Walk Away mode
• Turn on the BD Veritor Plus Analyzer by pressing the blue power button once.
The display window will briefly show “SCAN CONFIG BARCODE”. This is an
opportunity to change the configuration of the BD Veritor Plus Analyzer.
Please refer to the BD Veritor Plus Analyzer Instructions for Use for
configuration steps. Ignore this message and postpone this process when an
assay is awaiting analysis.
• When the display window reads: “INSERT TEST DEVICE OR DOUBLE CLICK FOR WALK
AWAY MODE”, double -click the blue power button.
Step 7D: Using the barcode scanner
• Follow the prompts on the display screen to complete any required barcode
scans of:
– OPERATOR ID
– SPECIMEN ID and/or
– KIT LOT NUMBER
- Prompts for each scanning step appear in the display window for only 30 seconds. Failure to complete scans during that time will cause the BD Veritor Plus Analyzer to default to the beginning of step 8C. To restart this step, remove and reinsert the test device to initiate a new reading sequence.
- Move barcodes slowly toward the window until a confirmation tone sounds. The scanned barcode value appears in the next display window.
- The BD Veritor Plus Analyzer can record the Kit Lot Number and expiration date in the test record but does not restrict the use of expired or inappropriate reagents. Management of expired materials is the responsibility of the user.
Step 8D: Adding the specimen to the test device
• When the display window reads: “ADD SPECIMEN TO TEST DEVICE AND INSERT
IMMEDIATELY”:
– Invert the tube, holding it vertically (approximately one inch above the BD
Veritor System SARS-CoV-2 device sample well).
– Gently squeeze the ridged portion of the tube, dispensing three (3) drops of
the processed specimen into the sample well.
– Excess volume remains for retesting if necessary.
NOTE: Squeezing the tube close to the tip may cause leakage.
_ CAUTION: A countdown timer displays the time remaining for test
insertion. Walk Away mode must be activated again _when this timer expires.
Confirm timer is visible and Walk Away mode is activated before inserting
test device.
Step 9D: Starting the development and reading sequence
• Insert the test device into the slot on the right side of the BD Veritor
Plus Analyzer. The test device must remain horizontal to prevent spilling the
specimen out of the sample well.
• “DO NOT DISTURB TEST IN PROGRESS” appears in the display window. Automatic
timing of the assay development, image processing and result analysis begins.
• The display window shows the remaining analysis time. Do not touch the BD
Veritor Plus Analyzer or remove the test device during this process. Doing so
will abort the assay analysis.
• When analysis is complete, a result appears in the display window. If
configured to display, the Specimen ID barcode value also appears. If a
printer is connected, specimen ID and result are automatically printed. If a
printer is not connected, record the result before removing the assay device.
_ ATTENTION: TEST Results are NOT maintained in the display window when the device is removed or if the BD Veritor _Plus Analyzer is left unattended for more than 15 minutes (60 minutes if AC power adapter is connected).
Step 10D: Removing the test device
• Remove and then discard the test device appropriately. The display will show
INSERT TEST DEVICE OR DOUBLE-CLICK BUTTON FOR WALK AWAY MODE to indicate the
BD Veritor Plus Analyzer is ready to perform another test. Note that the BD
Veritor Plus Analyzer returns to Analyze Now mode at the conclusion of each
read sequence. If the BD Veritor Plus Analyzer is connected to an LIS, a
steady ENVELOPE symbol will appear to indicate that results are awaiting
transmission. If a network connection is not detected while the ENVELOPE
symbol is still displayed, the BD Veritor Plus Analyzer will queue all
untransmitted results and attempt to transmit them when reconnected.
If it is powered off during this time, it will attempt to transmit as soon as power is restored, and connection is re-established. A flashing envelope indicates that data are in the process of being transmitted.
INTERPRETATION OF RESULTS
The BD Veritor Plus Analyzer (provided separately) must be used for interpretation of all test results. Operators should not attempt to interpret assay results directly from the test strip contained within the BD Veritor assay device.
*Invalid Test – If the test is invalid, the BD Veritor System Instrument will display “CONTROL INVALID” and the test or control must then be repeated. If the “CONTROL INVALID” reading recurs, contact BD.
REPORTING OF RESULTS
Positive Test – Positive for the presence of SARS-CoV-2 antigen.
Positive results indicate the presence of viral antigens, but clinical
correlation with patient history and other diagnostic information is necessary
to determine infection status. Positive results do not rule out bacterial
infection or co-infection with other viruses. The agent detected may not be
the definite cause of disease. Laboratories within the United States and its
territories are required to report all positive results to the appropriate
public health authorities.
Negative Test – Negative results are presumptive. Negative test
results do not preclude infection and should not be used as the sole basis for
treatment or other patient management decisions, including infection control
decisions, particularly in the presence of clinical signs and symptoms
consistent with COVID-19, or in those who have been in contact with the virus.
It is recommended that these results be confirmed by a molecular testing
method, if necessary, for patient management. Control Invalid – Do not report
results. Repeat the test.
QUALITY CONTROL
Each BD Veritor System SARS-CoV-2 test device contains both positive and
negative internal/procedural controls:
• The internal positive control line validates the immunological integrity of
the device, proper reagent function, and assures correct test procedure.
• The membrane area surrounding test lines functions as a background check on
the assay device. The BD Veritor System Instrument evaluates the positive and
negative internal/procedural controls after insertion of each test device. The
BD Veritor Plus Analyzer prompts the operator if a quality issue occurs during
assay analysis. Failure of the internal/procedural controls will generate an
invalid test result. NOTE: The internal controls do not assess proper sample
collection technique.
EXTERNAL POSITIVE AND NEGATIVE CONTROLS
Positive and Negative control swabs are supplied with each kit. These controls
provide additional quality control material to assess that the test reagents
and the BD Veritor System Instrument perform as expected. Prepare kit control
swabs and test using the same procedure as used for patient specimens. BD
recommends controls be run once for:
• each new kit lot,
• each new operator,
• as required by internal quality control procedures and in accordance with
local, state and federal regulations or accreditation requirements.
If the kit controls do not perform as expected, do not report patient results.
Contact BD Technical Services at 1.800.638.8663.
LIMITATIONS OF THE PROCEDURE
• Clinical performance was evaluated with frozen samples, and test performance
may be different with fresh samples.
• Users should test specimens as quickly as possible after specimen
collection.
• Positive test results do not rule out co-infections with other pathogens.
• Results from the BD Veritor System for Rapid Detection of SARS-CoV-2 test
should be correlated with the clinical history, epidemiological data, and
other data available to the clinician evaluating the patient.
• A false-negative test result may occur if the level of viral antigen in a
sample is below the detection limit of the test or if the sample was collected
or transported improperly; therefore, a negative test result does not
eliminate the possibility of SARS-CoV-2 infection.
• The amount of antigen in a sample may decrease as the duration of illness
increases. Specimens collected after day 5 of illness are more likely to be
negative compared to a RT-PCR assay.
• Failure to follow the test procedure may adversely affect test performance
and/or invalidate the test result.
• The contents of this kit are to be used for the qualitative detection of
SARS-CoV-2 antigens from nasal swab specimens only.
• The BD Veritor System for Rapid Detection of SARS-Cov-2 can detect both
viable and non-viable SARS-CoV-2 material. The BD Veritor System for Rapid
Detection of SARS-CoV-2 performance depends on antigen load and may not
correlate with other diagnostic methods performed on the same specimen.
• Negative test results are not intended to rule in other non-SARS-CoV-2 viral
or bacterial infections.
• Positive and negative predictive values are highly dependent on prevalence
rates. Positive test results are more likely to represent false positive
results during periods of little/no SARS-CoV-2 activity when disease
prevalence is low. False negative test results are more likely when prevalence
of disease caused by SARS-CoV-2 is high.
• This device has been evaluated for use with human specimen material only. •
Monoclonal antibodies may fail to detect, or detect with less sensitivity,
SARS-CoV-2 viruses that have undergone minor amino acid changes in the target
epitope region.
• The performance of this test has not been evaluated for use in patients
without signs and symptoms of respiratory infection and performance may differ
in asymptomatic individuals.
• Sensitivity of the test after the first five days of the onset of symptoms
has been demonstrated to decrease as compared to a RT-PCR SARS-CoV-2 assay.
• Negative results should be treated as presumptive and confirmed with an FDA
authorized molecular assay, if necessary, for clinical management, including
infection control.
• Specimen stability recommendations are based upon stability data from
influenza testing and performance may be different with SARS-CoV-2. Users
should test specimens as quickly as possible after specimen collection, and
within one hour after specimen collection.
• The validity of the BD Veritor System for Rapid Detection of SARS-CoV-2 test
has not been proven for identification/confirmation of tissue culture isolates
and should not be used in this capacity.
CONDITIONS OF AUTHORIZATION FOR THE LABORATORY (APPLICABLE IN THE USA)
The BD Veritor System for Rapid Detection of SARS-CoV-2 Letter of
Authorization, along with the authorized Fact Sheet for Healthcare Providers,
the authorized Fact Sheet for Patients, and authorized labeling are available
on the FDA website: https://www.fda.gov/medical devices/emergency-use-
authorizations-medical-devices/coronavirus-disease-2019-covid-19-emergency-
use-authorizations-medical-devices.
However, to assist clinical laboratories using the BD Veritor System for Rapid
Detection of SARS-CoV-2 (“your product” in the conditions below), the relevant
Conditions of Authorization are listed below.
• Authorized laboratories* using your product will include with test result
reports, all authorized Fact Sheets. Under exigent circumstances, other
appropriate methods for disseminating these Fact Sheets may be used, which may
include mass media.
• Authorized laboratories using your product will use your product as outlined
in the “BD Veritor System for Rapid Detection of SARS-CoV-2” Instructions for
Use. Deviations from the authorized procedures, including the authorized
instruments, authorized clinical specimen types, authorized control materials,
authorized other ancillary reagents and authorized materials required to use
your product are not permitted.
• Authorized laboratories that receive your product will notify the relevant
public health authorities of their intent to run your product prior to
initiating testing.
• Authorized laboratories using your product will have a process in place for
reporting test results to healthcare providers and relevant public health
authorities, as appropriate.
• Authorized laboratories will collect information on the performance of your
product and report to DMD/OHT7-OIR/ OPEQ/CDRH (via email: CDRH-EUA-
Reporting@fda.hhs.gov) and to BD by
contacting BD
Customer Support
Services at 800.638.8663 (in the U.S.) any suspected occurrence of false
positive or false negative results and significant deviations from the
established performance characteristics of your product of which they become
aware.
• All operators using your product must be appropriately trained in performing
and interpreting the results of your product, use appropriate personal
protective equipment when handling this kit, and use your product in
accordance with the authorized labeling.
• Becton, Dickinson and Co., authorized distributors, and authorized
laboratories and patient care settings using your product will ensure that any
records associated with this EUA are maintained until otherwise notified FDA.
Such records will be made available to FDA for inspection upon request.
*The letter of authorization refers to, “Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.” as “authorized laboratories”.
CLINICAL PERFORMANCE
The performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 was
established with 226 direct nasal swabs prospectively collected and enrolled
from individual symptomatic patients (within 5 days of onset) who were
suspected of COVID-19. As with all antigen tests, performance may decrease as
days since symptom onset increases. Samples were collected by qualified
personnel in 21 geographically diverse areas across the United States. Nasal
swabs were collected following the dual nares method and handled as described
in the package insert of the collection
device. Specimens were frozen within 30 minutes of collection and stored until
tested. All specimens within a pre-specified date range were selected and then
sequentially tested in a blinded fashion. The performance of the BD Veritor
System Assay was compared to results of a nasopharyngeal or oropharyngeal swab
stored in 3 mL viral transport media tested with an Emergency Use Authorized
molecular (RT-PCR) test for detection of SARS CoV-2.
Table 1
Summary of the Performance of the BD Veritor System for Rapid Detection of
SARS-CoV-2 Compared to RT-PCR for Nasal Swabs.
PPA: 84% (C.I. 67%–93%) PPV: 100% (C.I. 89%, 100%)
NPA: 100% (C.I. 98%–100%) NPV: 97.5% (C.I. 95%, 99%)
OPA: 98% (C.I. 95%–99%)
EXPLANATION OF TERMS:
C.I.: Confidence Interval
PPA: Positive Percent Agreement = True Positives / True Positives + False
Negatives
NPA: Negative Percent Agreement = True Negatives / True Negatives + False
Positives.
OPA: Overall Percent Agreement = True Positives + True Negatives / Total
Samples
PPV: Positive Predictive Value = True Positives / True Positive + False
Positive
NPV: Negative Predictive Value = True Negatives / True Negative + False
Negative
Table 2
Hypothetical Positive and Negative Predictive Values for the BD Veritor System
for Rapid Detection of SARS-CoV-2 compared to PCR.
EXPLANATION OF TERMS:
C.I.: Confidence Interval
PPV: Positive Predictive Value = True Positives / True Positive + False
Positive
NPV: Negative Predictive Value = True Negatives / True Negative + False
Negative
ANALYTICAL PERFORMANCE
LIMIT OF DETECTION (ANALYTICAL SENSITIVITY)
The LOD for the BD Veritor System for Rapid Detection of SARS-CoV-2 was
established using limiting dilutions of a viral sample inactivated by gamma
irradiation. The material was supplied at a concentration of 2.8 x 105
TCID50/mL. In this study, designed to estimate the LOD of the assay when using
a direct nasal swab, the starting material was spiked into a volume
of pooled human nasal matrix obtained from healthy donors and confirmed
negative for SARS-CoV-2. An initial range finding study was performed testing
devices in triplicate using a 10-fold dilution series. At each dilution, 50 μL
samples were added to swabs and then tested in the BD Veritor assay using the
procedure appropriate for patient nasal swab specimens. A
concentration was chosen between the last dilution to give 3 positive results
and the first to give 3 negative results. Using this concentration, the LOD
was further refined with a 2-fold dilution series. The last dilution
demonstrating 100% positivity was then tested in an additional 20 replicates
tested in the same way.
CROSS REACTIVITY (ANALYTICAL SPECIFICITY)
Cross-reactivity of the BD Veritor System for Rapid Detection of SARS-CoV-2 was evaluated by testing a panel of high prevalence respiratory pathogens that could potentially cross-react with the BD Veritor System for Rapid Detection of SARS-CoV-2. Each organism and virus was tested in triplicate. The final concentration of each organism is documented in the following table.
To estimate the likelihood of cross-reactivity with SARS-CoV-2 of organisms
that were not available for wet testing, In silico analysis using the Basic
Local Alignment Search Tool (BLAST) managed by the National Center for
Biotechnology Information (NCBI) was used to assess the degree of protein
sequence homology.
• For P. jirovecii one area of sequence similarity shows 45.4% homology across
9% of the sequence, making cross-reactivity in the BD Veritor sandwich
immunoassay highly unlikely.
• No protein sequence homology was found between SARS-CoV-2 and M.
tuberculosis, and thus homology-based cross-reactivity can be ruled out.
• The comparison between SARS-CoV-2 nucleocapsid protein and human coronavirus
HKU1 revealed that the only potential for homology is with the HKU1
nucleocapsid phosphoprotein. Homology is relatively low, at 36.7% across 82%
of sequences, but cross-reactivity cannot be ruled out.
HIGH DOSE HOOK EFFECT
No high dose hook effect was observed up to 2.8 x 105 TCID50/mL of gamma- inactivated SARS-CoV-2 with the BD Veritor System for Rapid Detection of SARS- CoV-2 test.
TECHNICAL SUPPORT
For questions, or to report a problem, please call Technical Support at 1.800.638.8663. Test system problems may also be reported to the FDA using the MedWatch reporting system: (phone: 1.800.FDA.1088; fax: 1.800.FDA.1078; or http://www.fda.gov/medwatch).
REFERENCES
1. Centers for Disease Control and Prevention.
https://www.cdc.gov/coronavirus/2019-ncov/index.html Accessed March 30,
2020.
2. bioRxiv. (https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1).
Accessed March 30, 2020.
3. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm.
Technical Information: In the United States contact BD Technical Service and
Support at 1.800.638.8663 or bd.com.
BD Veritor System Rapid SARS-CoV-2 Test Instructions For Use – Optimized
PDF
BD Veritor System Rapid SARS-CoV-2 Test Instructions For Use – Original
PDF